Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer

The Pharmacogenomics Journal volume 11, pages 53–60 (2011)Cite this article

Subjects

Abstract

Single-nucleotide polymorphisms (SNPs) in the vascular endothelial growth factor A (VEGF-A) gene may have clinical implications. The aim of this study was to investigate the possible predictive value of the VEGF-A SNPs, in patients with metastatic colorectal cancer (mCRC) treated with first-line capecitabine and oxaliplatin (XELOX). The study included 72 patients with mCRC. Genomic DNA was isolated from whole blood, and SNPs were analyzed by PCR. SNPs were correlated with response and progression-free survival (PFS). Haplotypes were estimated using the PHASE program. Response was observed in 21% of the patients with the −2578 CA genotype compared with 59% of the patients with CC+AA, P=0.002, in 26% of the patients with the −460 CT genotype compared with 57% with CC+TT, P=0.01, and in 27% of the patients with the +405 GC genotype compared with 54% with GG+CC, P=0.02. Two SNPs were significantly related to PFS. A haplotype with a significant relationship to response was identified. The results demonstrated obvious relationships between genetic variations in the VEGF-A gene and response to first-line XELOX in patients with mCRC, which translated to a significant difference in PFS. The results call for validation in a larger cohort of patients.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY et al. Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 2008; 14: 62–66.

    Article  CAS  PubMed  Google Scholar 

  2. Lurje G, Zhang W, Schultheis AM, Yang D, Groshen S, Hendifar AE et al. Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer. Ann Oncol 2008; 19: 1734–1741.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Yamamori M, Sakaeda T, Nakamura T, Okamura N, Tamura T, Aoyama N et al. Association of VEGF genotype with mRNA level in colorectal adenocarcinomas. Biochem Biophys Res Commun 2004; 325: 144–150.

    Article  CAS  PubMed  Google Scholar 

  4. Ferrara N, Gerber HP, LeCouter J . The biology of VEGF and its receptors. Nat Med 2003; 9: 669–676.

    Article  CAS  PubMed  Google Scholar 

  5. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK . Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004; 64: 3731–3736.

    Article  CAS  PubMed  Google Scholar 

  6. Jain RK . Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307: 58–62.

    Article  CAS  PubMed  Google Scholar 

  7. Willett CG, Boucher Y, di TE, Duda DG, Munn LL, Tong RT et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004; 10: 145–147.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Negri FV, Campanini N, Camisa R, Pucci F, Bui S, Ceccon G et al. Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy. Br J Cancer 2008; 98: 143–147.

    Article  CAS  PubMed  Google Scholar 

  9. Spindler KL, Nielsen JN, Lindebjerg J, Brandslund I, Jakobsen A . Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 2006; 66: 500–504.

    Article  PubMed  Google Scholar 

  10. Vincenzi B, Santini D, Russo A, Gavasci M, Battistoni F, Dicuonzo G et al. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan. Pharmacogenomics 2007; 8: 319–327.

    Article  CAS  PubMed  Google Scholar 

  11. Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial. J Clin Oncol 2008; 26: 2690–2698.

    CAS  PubMed  Google Scholar 

  12. Jensen LH, Danenberg KD, Danenberg PV, Jakobsen A . Predictive value of MSH2 gene expression in colorectal cancer treated with capecitabine. Clin Colorectal Cancer 2007; 6: 433–435.

    Article  CAS  PubMed  Google Scholar 

  13. Qiu LX, Tang QY, Bai JL, Qian XP, Li RT, Liu BR et al. Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: evidence from 24 studies. Int J Cancer 2008; 123: 2384–2389.

    Article  CAS  PubMed  Google Scholar 

  14. van Kuilenburg AB . Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 2004; 40: 939–950.

    Article  CAS  PubMed  Google Scholar 

  15. Uchida K, Danenberg PV, Danenberg KD, Grem JL . Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of oxaliplatin and capecitabine. BMC Cancer 2008; 8: 386.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Pare L, Marcuello E, Altes A, del RE, Sedano L, Salazar J et al. Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 2008; 99: 1050–1055.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008; 26: 4672–4678.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Stephens M, Smith NJ, Donnelly P . A new statistical method for haplotype reconstruction from population data. Am J Hum Genet 2001; 68: 978–989.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Stephens M, Scheet P . Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet 2005; 76: 449–462.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Park HM, Hong SH, Kim JW, Oh D, Hwang SG, An HJ et al. Gender-specific association of the VEGF −2578C > A polymorphism in Korean patients with colon cancer. Anticancer Res 2007; 27: 2535–2539.

    CAS  PubMed  Google Scholar 

  21. Lu H, Shu XO, Cui Y, Kataoka N, Wen W, Cai Q et al. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res 2005; 65: 5015–5019.

    Article  CAS  PubMed  Google Scholar 

  22. Chae YS, Kim JG, Sohn SK, Cho YY, Ahn BM, Moon JH et al. Association of vascular endothelial growth factor gene polymorphisms with susceptibility and clinicopathologic characteristics of colorectal cancer. J Korean Med Sci 2008; 23: 421–427.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Cacev T, Loncar B, Seiwerth S, Spaventi S, Kapitanovic S . Vascular endothelial growth factor polymorphisms −1154 G/A and −460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol 2008; 27: 569–574.

    Article  CAS  PubMed  Google Scholar 

  24. Smerdel MP, Waldstrom M, Brandslund I, Steffensen KD, Andersen RF, Jakobsen A . Prognostic importance of vascular endothelial growth factor-A expression and vascular endothelial growth factor polymorphisms in epithelial ovarian cancer. Int J Gynecol Cancer 2009; 19: 578–584.

    Article  PubMed  Google Scholar 

  25. Hofmann G, Langsenlehner U, Renner W, Langsenlehner T, Yazdani-Biuki B, Clar H et al. Common single nucleotide polymorphisms in the vascular endothelial growth factor gene and colorectal cancer risk. J Cancer Res Clin Oncol 2008; 134: 591–595.

    Article  CAS  PubMed  Google Scholar 

  26. Maltese P, Canestrari E, Ruzzo A, Graziano F, Falcone A, Loupakis F et al. VEGF gene polymorphisms and susceptibility to colorectal cancer disease in Italian population. Int J Colorectal Dis 2008; 24: 165–170.

    Article  PubMed  Google Scholar 

  27. Saltz LB, Clarke S, az-Rubio E, Scheithauer W, Figer A, Wong R et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013–2019.

    Article  CAS  PubMed  Google Scholar 

  28. Shahbazi M, Fryer AA, Pravica V, Brogan IJ, Ramsay HM, Hutchinson et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol 2002; 13: 260–264.

    CAS  PubMed  Google Scholar 

  29. Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E . VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004; 46: 293–298.

    Article  PubMed  Google Scholar 

  30. Hansen TF, Spindler KL, Lorentzen KA, Olsen DA, Andersen RF, Lindebjerg J et al. The importance of −460 C/T and +405 G/C single nucleotide polymorphisms to the function of vascular endothelial growth factor A in colorectal cancer. J Cancer Res Clin Oncol 2009; e-pub ahead of print 11 November 2009; doi:10.1007/s00432-009-0714-1.

    Article  PubMed  Google Scholar 

  31. Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002; 51: 1635–1639.

    Article  CAS  PubMed  Google Scholar 

  32. Watson CJ, Webb NJ, Bottomley MJ, Brenchley PE . Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: correlation with variation in VEGF protein production. Cytokine 2000; 12: 1232–1235.

    Article  CAS  PubMed  Google Scholar 

  33. Renner W, Kotschan S, Hoffmann C, Obermayer-Pietsch B, Pilger E . A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J Vasc Res 2000; 37: 443–448.

    Article  CAS  PubMed  Google Scholar 

  34. Krippl P, Langsenlehner U, Renner W, Yazdani-Biuki B, Wolf G, Wascher TC et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int J Cancer 2003; 106: 468–471.

    Article  CAS  PubMed  Google Scholar 

  35. Dassoulas K, Gazouli M, Rizos S, Theodoropoulos G, Christoni Z, Nikiteas N et al. Common polymorphisms in the vascular endothelial growth factor gene and colorectal cancer development, prognosis, and survival. Mol Carcinog 2009; 48: 563–569.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We are very thankful for the technical assistance provided by Lone Frischknecht, Lone Hartmann Hansen, Sara Egsgaard and Birgit Roed Sørensen, for the proofreading by Karin Larsen and for the genetic counseling provided by Steen Kølvraa. No writing assistance was provided. The study was supported by The Cancer Foundation, which had no involvement in any part of the study.

Author information

Authors and Affiliations

  1. Department of Oncology, Danish Colorectal Cancer Group South, Vejle Hospital, Vejle, Denmark

    T F Hansen, K-L Garm Spindler & A Jakobsen

  2. Department of Biochemistry, Danish Colorectal Cancer Group South, Vejle Hospital, Vejle, Denmark

    R F Andersen & I Brandslund

  3. Department of Clinical Pathology, Danish Colorectal Cancer Group South, Vejle Hospital, Vejle, Denmark

    J Lindebjerg

Authors
  1. T F Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K-L Garm Spindler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R F Andersen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J Lindebjerg
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. I Brandslund
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Jakobsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T F Hansen.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hansen, T., Garm Spindler, KL., Andersen, R. et al. The predictive value of genetic variations in the vascular endothelial growth factor A gene in metastatic colorectal cancer. Pharmacogenomics J 11, 53–60 (2011). https://doi.org/10.1038/tpj.2010.4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2010.4

Keywords

This article is cited by

Search

Advanced search

Quick links